Emergent BioSolutions Slashes Jobs, Widens Loss, and Slashes FY26 Outlook
EBS is trading near its 52-week low of $5.87 (1.7% above the low).
Summary
Emergent BioSolutions is cutting 93 jobs and restructuring to save $40 million, while reporting a dramatically wider Q2 loss of $180.2 million versus $12 million a year ago. Revenue rose to $234.3 million, but the company slashed its full-year revenue guidance to $645-$675 million from $720-$760 million and now expects a net loss of $225-$245 million, a massive swing from the prior $10-$30 million loss forecast. The restructuring creates a new growth organization combining R&D, business development, and strategy. This follows a series of government contract wins in recent months, but the deteriorating financials and outlook overshadow those positives. The stock is trading near its 52-week low, and the guidance cut signals deeper operational challenges.
At the time of this announcement, EBS was trading at $5.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $389M. The 52-week trading range was $5.87 to $14.06. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.